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Drug interactions
The chemicals in smoke may interact with 
antipsychotics, antidepressants, benzodiazepines,8 
oral contraceptives, inhaled corticosteroids and beta 
blockers via pharmacokinetic and pharmacodynamic 
(often nicotine-mediated) mechanisms.9
Pharmacokinetic interactions
Cigarette smoking induces the activity of cytochrome 
P450 (CYP) 1A2 (via chemicals in cigarette smoke 
such as polycyclic aromatic hydrocarbons)10 and also 
CYP2B6.11 These enzymes metabolise several clinically 
important drugs (such as antidepressants and 
antipsychotics) (Box) and a number of procarcinogens 
(such as those in cigarettes).10,12
The effect of smoking on hepatic enzymes is not 
related to the nicotine component of tobacco. 
Nicotine replacement therapy does not influence 
CYP1A2 activity.13
Genetic polymorphisms of the CYP1A2 gene 
contribute to extensive inter-individual variability in 
drug metabolism14,15 and are associated with altered 
inducibility of gene expression in smokers.7,16 There 
are also marked ethnic differences in the distribution 
of CYP1A2 mutations,10,17 meaning that different ethnic 
groups respond differently when the patient stops 
smoking. 
CYP1A2 activity is significantly higher in heavy 
smokers (more than 20 cigarettes/day) than in non-
smokers.18 This is likely to be clinically relevant for 
some drugs which have a narrow therapeutic index 
and are metabolised by CYP1A2, such as clozapine. 
The induction varies depending on the bioavailability 
of the components of cigarette smoke and the extent 
of inhalation.8 It is not known how the number of 
cigarettes smoked daily or inter-individual variation 
affects CYP1A2 induction,9 but heavier smokers appear 
to have a greater increase in the clearance of drugs.19
This enzyme induction is rapidly reversed when 
patients abruptly stop smoking, with a new steady 
state of CYP1A2 activity reached after approximately 
one week.20 This reduction in enzyme activity reduces 
clearance and increases the risk of adverse drug 
reactions for patients taking drugs metabolised by 
CYP1A2.20,21 These patients should be regularly asked 
about their smoking and the extent of their cigarette 
consumption.16
Clozapine and olanzapine
Cigarette smoking induces the metabolism of 
Introduction
Despite anti-smoking campaigns, there are about  
1.3 billion cigarette smokers worldwide and this 
number is still increasing.1 Both smoking prevalence 
and daily tobacco consumption are very high in 
patients with psychiatric disorders.2 Over two-thirds 
of Australians with psychosis smoke cigarettes, 
compared with one quarter of the general population.3
Smoking restriction or cessation is now commonly 
imposed on patients by ‘no smoking’ policies in 
Australian hospitals. Stopping smoking is particularly 
important in patients with mental health problems as 
they often have an adverse cardiovascular risk profile 
(from factors including obesity, dyslipidaemia, insulin 
resistance and hypertension). This is associated with 
high rates of premature mortality from cardiovascular 
disease.4
Even with nicotine replacement therapy as a cessation 
aid, patients with psychiatric illness appear to have 
more difficulty maintaining long-term abstinence 
than other smokers.5 Most resume smoking within 
five weeks of hospital discharge.6 These patients 
should be regularly asked about their smoking 
status, as an additional risk of resuming or abruptly 
ceasing cigarette smoking has the potential for drug 
interactions.7
SUMMARY
When patients enter hospital they may have 
to stop smoking abruptly if the hospital 
has a ‘no smoking’ policy. Abrupt smoking 
cessation can affect the metabolism of drugs.
Cigarette smoking induces the activity of 
human cytochromes P450 (CYP) 1A2 and 
2B6. These enzymes metabolise several 
clinically important drugs, including 
clozapine, olanzapine and methadone. 
Decreased CYP1A2 activity after smoking 
cessation increases the risk of adverse 
drug reactions, with reports of increased 
toxicity from clozapine and olanzapine. 
Predicting the required dose reduction of 
drugs metabolised by CYP1A2 after smoking 
cessation is challenging. Therapeutic drug 
monitoring should be used when possible.  
Nicotine replacement therapy does not 
influence CYP1A2 activity.
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the warfarin dose requirement by 12%, resulting in 
an extra 2.26 mg per week compared with non-
smoking.30 Consequently, INR should be closely 
monitored when there is a change in patients’ 
smoking status.
Clopidogrel and prasugrel
CYP isoenzymes (including CYP2C19, 3A4/5, 1A2, 
2B6 and 2C9) convert clopidogrel and prasugrel 
into their active metabolites, which bind irreversibly 
to the receptors on platelets. As smoking is 
known to enhance CYP1A2 activity, theoretically 
it could increase the antiplatelet efficacy of these 
thienopyridine drugs.31
An enhanced response to clopidogrel has been 
seen in smokers who are CYP1A2 (163CA) A-allele 
carriers.32 Two retrospective analyses of large 
randomised clinical trials of clopidogrel showed 
that clopidogrel might be more effective in active 
smokers.33,34 However, a systematic review concluded 
that smoking is not associated with reduced platelet 
reactivity in patients on clopidogrel.31 Genetic 
polymorphisms seem not to impact on the activity of 
prasugrel.31
Caffeine
Caffeine is highly dependent on CYP1A2 for its 
metabolism. Smokers require up to four times as 
much caffeine as non-smokers to achieve the same 
plasma caffeine concentration. Caffeine can increase 
the concentration of clozapine and olanzapine.35
Pharmacodynamic drug interactions
Pharmacodynamic drug interactions with tobacco 
smoke are largely due to nicotine.9
Methadone
The vast majority of patients using methadone 
maintenance therapy also smoke tobacco.36 
Methadone doses have been found to be higher 
in heavy smokers37 and methadone has been 
shown to increase both smoking rates and smoking 
satisfaction.38 Patients report less methadone-induced 
clozapine and olanzapine,22 resulting in lower 
plasma concentrations.7,16,21 The daily consumption 
of 7–12 cigarettes is probably sufficient to cause the 
maximum induction of clozapine and olanzapine 
metabolism.22 A 50% difference in the mean daily 
dose of clozapine needed by smokers and non-
smokers to reach a given blood concentration has 
been reported.23
Irrespective of smoking status, the mean oral 
bioavailability of clozapine is 27–47% and clozapine 
plasma concentrations have more than a 45-fold 
variability amongst individuals during chronic 
treatment.24 There are also large inter-patient 
differences in olanzapine exposure, with gender and 
genetic factors contributing.25
Non-smokers are at higher risk of adverse effects if 
treated with standard doses, suggesting that there 
is an interaction between smoking, olanzapine and 
clozapine.20,22 In one case report, a patient receiving 
olanzapine experienced extrapyramidal symptoms 
(including akathisia, akinesia and bradyphrenia) within 
days of significantly reducing tobacco consumption.21 
Case reports on smoking discontinuation by patients 
taking clozapine outline effects including confusion,21 
tonic–clonic seizures, stupor, coma26 or aspiration 
pneumonia.27
Clearance of clozapine has been shown to decrease 
when smoking is ceased, with a mean increase of 72% 
in plasma clozapine concentrations.27 It is suggested 
that daily dose reductions (of approximately 10% 
until the fourth day after smoking cessation) should 
be made whenever patients cease smoking during 
treatment with clozapine.20 Patients who resume 
smoking after leaving hospital may need their drugs 
and doses reviewed to account for this change.28 
Therapeutic drug monitoring of clozapine is useful.
Antidepressants
As fluvoxamine is metabolised by CYP1A2, smokers 
might require higher doses than those recommended 
from clinical trial data.8 Smoking is not anticipated to 
alter the pharmacokinetics of other selective serotonin 
reuptake inhibitors as they are not substrates of 
CYP450 isoenzymes induced by smoking.8
Smokers might require higher than normal doses of 
the tricyclic antidepressant imipramine. They do not 
appear to require dose adjustments of amitriptyline, 
nortriptyline or clomipramine.8
Warfarin
Warfarin’s less active R isomer is eliminated to a 
minor extent by CYP1A2.29 Smoking may therefore 
potentially interact with warfarin by increasing its 
clearance and reducing its effect. A recent meta-
analysis showed that smoking appeared to increase 
Box    Substrates of some cytochrome P450 enzymes induced 
by smoking
CYP1A2 
amitriptyline, caffeine, clozapine, duloxetine, fluvoxamine, haloperidol, imipramine, 
olanzapine, ondansetron, paracetamol, propranolol, theophylline, warfarin (R-isomer)
CYP2B6
bupropion, clopidogrel, cyclophosphamide, efavirenz, ifosfamide, methadone, 
nevirapine
More comprehensive lists are available8,17
Adapted from Australian Medicines Handbook 2013
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Drugs for nicotine dependence
Drugs used to aid smoking cessation are not without 
their hazards, particularly in patients with psychiatric 
disorders.
Bupropion, a selective catecholamine reuptake 
inhibitor, is associated with a dose-related risk of 
seizures. Predisposing risk factors include concomitant 
administration of antipsychotics, antidepressants, 
excessive alcohol or those sedatives which lower 
the seizure threshold. Psychiatric symptoms, in 
particular psychosis or mania, have been observed, 
mainly in patients with a history of psychiatric illness, 
particularly bipolar disorder. 
Bupropion is metabolised by CYP2B6 and inhibits 
the CYP2D6 pathway. Drugs predominantly 
metabolised by 2D6 (including metoprolol, many 
antidepressants and antipsychotics) should be started 
at the lower end of the dose range if bupropion is 
used. Co-administration of drugs known to induce 
metabolism (for example, carbamazepine and 
phenytoin) or inhibit metabolism (for example, 
valproate) may affect the activity of bupropion. 
Nortriptyline, a tricyclic antidepressant shown to aid 
smoking cessation, also interacts with other drugs 
metabolised by CYP2D6. 
Varenicline, a partial agonist at neuronal nicotinic 
acetylcholine receptors, has no known clinically 
significant drug interactions. However, using nicotine 
replacement therapy while taking varenicline can 
exacerbate adverse effects such as nausea and 
headache. As with bupropion, serious neuropsychiatric 
symptoms have been reported (although a causal 
association has not been established). 
Conclusion
Cigarette smoking can affect drug metabolism via 
pharmacokinetic and pharmacodynamic mechanisms, 
and a change in smoking status can render patients at 
risk of serious adverse reactions.
Patients should be regularly monitored with regard 
to their smoking status and extent of cigarette 
consumption and doses of relevant medications 
adjusted accordingly. 
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sedation when they smoke around the time of their 
methadone dose.39
Although methadone is a CYP2B6 substrate (Box), 
nicotine affects the endogenous opioid system. 
Cigarette smoking enhances the effect of methadone 
on opioid withdrawal symptoms.40
Methadone attenuates nicotine withdrawal. Reducing 
methadone doses when the patient is trying to stop 
smoking could be detrimental.40
Benzodiazepines
Nicotine activates the central nervous system9 and 
this may explain the attenuated sedation observed 
in smokers compared to non-smokers taking 
benzodiazepines.41 Prescribers should be aware that 
when patients taking benzodiazepines stop smoking, 
there is a risk of central nervous system depression. 
Oral contraception
Smoking increases the adverse effects of the 
combined oral contraceptive pill (specifically 
thromboembolism, ischaemic stroke and myocardial 
infarction). The combined oral contraceptive pill is 
contraindicated in women aged 35 years or older 
who smoke 15 or more cigarettes a day.9 For smokers 
who use combined low-dose oral contraceptives, the 
attributable risk of death from cardiovascular disease 
is 19.4 per 100 000 women aged 35–44 years  
(vs 3.03 per 100 000 for non-smoking women of the 
same age).42 This risk is also presumed to be associated 
with other contraceptives containing oestrogen.9
Limited data suggest no convincing association 
between cardiovascular disease and progestogen-
only pill use.43 If smoking cessation is unsuccessful, 
non-hormonal or progestogen-only contraceptives 
are preferred from a cardiovascular perspective.9
Other drugs
The efficacy of inhaled corticosteroids may be 
reduced in asthmatic patients who smoke,9 so these 
patients might require higher doses of inhaled 
corticosteroids to attain asthma control.44
Proposed mechanisms of corticosteroid insensitivity 
include suppression of histone deacetylase 
expression and activity by cigarette smoking, causing 
inflammatory gene expression and a reduction in 
glucocorticoid function.45 Clearance of corticosteroids 
from the lungs may be altered by increased mucus 
secretion or airway permeability.46
Smokers may require higher doses of beta blockers. 
Although propranolol is a CYP1A2 substrate (Box), 
nicotine-mediated central nervous system activation 
may diminish the effect of beta blockers on blood 
pressure and heart rate.9
SELF-TEST 
QUESTIONS
True or false? 
9. As smoking induces 
cytochrome P450 1A2,  
smokers need lower 
doses of drugs 
metabolised by this 
enzyme.
10. The pharmacokinetic 
effects caused by 
stopping smoking can 
be avoided by giving 
the patient a nicotine 
patch.
Answers on page 107
ARTICLE
Full text free online at www.australianprescriber.com
VOLUME 36 : NUMBER 3 : JUNE 2013
104a
1. Guindon GE, Boisclair D. Past, current and future trends in tobacco use. 
Health, Nutrition and Population (NHP) discussion paper. Economics of 
tobacco control paper No. 6. Washington DC: World Bank; 2003.
2. Keizer I, Eytan A. Variations in smoking during hospitalization in psychiatric 
in-patient units and smoking prevalence in patients and health-care staff.  
Int J Soc Psychiatry 2005;51:317-28.
3. Morgan VA, Waterreus A, Jablensky A, Mackinnon A, McGrath JJ, Carr V, et al. 
People living with psychotic illness 2010. Report on the second Australian 
national survey. Canberra: Department of Health and Ageing; 2011. 
4. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and 
increased risks of cardiovascular disease. Am Heart J 2005;150:1115-21.
5. Siru R, Hulse GK, Khan RJ, Tait RJ. Motivation to quit smoking among 
hospitalised individuals with and without mental health disorders.  
Aust N Z J Psychiatry 2010;44:640-7.
6. Prochaska JJ, Fletcher L, Hall SE, Hall SM. Return to smoking following a 
smoke-free psychiatric hospitalization. Am J Addict 2006;15:15-22.
7. Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB. Impact of 
smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity 
and inducibility. Clin Pharmacol Ther 2011;90:117-25.
8. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic 
medications: a pharmacokinetic perspective. CNS Drugs 2001;15:469-94.
9. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm 
2007;64:1917-21.
10. Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E. Insights into the substrate 
specificity, inhibitors, regulation, and polymorphisms and the clinical impact 
of human cytochrome P450 1A2. AAPS J 2009;11:481-94.
11. Washio I, Maeda M, Sugiura C, Shiga R, Yoshida M, Nonen S, et al. Cigarette 
smoke extract induces CYP2B6 through constitutive androstane receptor in 
hepatocytes. Drug Metab Dispos 2011;39:1-3.
12. Rendic S. Summary of information on human CYP enzymes: human P450 
metabolism data. Drug Metab Rev 2002;34:83-448.
13. Schaffer SD, Yoon S, Zadezensky I. A review of smoking cessation: potentially 
risky effects on prescribed medications. J Clin Nurs 2009;18:1533-40.
14. Cascorbi I. Genetic basis of toxic reactions to drugs and chemicals.  
Toxicol Lett 2006;162:16-28.
15. Palma BB, Silva e Sousa M, Vosmeer CR, Lastdrager J, Rueff J, Vermeulen NP,  
et al. Functional characterization of eight human cytochrome P450 1A2 
gene variants by recombinant protein expression. Pharmacogenomics J 
2010;10:478-88.
16. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB. Increased 
clozapine plasma concentrations and side effects induced by smoking 
cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005;27:539-43.
17. Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and 
polymorphism and the clinical significance of human cytochrome P450 1A2. 
Drug Metab Rev 2010;42:268-354.
18. Tantcheva-Poor I, Zaigler M, Rietbrook S, Fuhr U. Estimation of cytochrome 
P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based 
caffeine test. Phamacogenetics 1999;9:131-44.
19. Jusko WJ. Influence of cigarette smoking on drug metabolism in man.  
Drug Metab Rev 1979;9:221-36.
20. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on 
cessation of heavy smoking. Clin Pharmacol Ther 2004;76:178-84.
21. Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P. Tobacco and cannabis 
smoking cessation can lead to intoxication with clozapine or olanzapine.  
Int Clin Psychopharmacol 2002;17:141-3.
22. Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H. The effect of variable 
cigarette consumption on the interaction with clozapine and olanzapine.  
Eur J Clin Pharmacol 2006;62:1049-53.
23. van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and 
cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and 
dose requirement. Pharmacogenetics 2003;13:169-72.
24. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, et al. Plasma 
clozapine concentrations predict clinical response in treatment-resistant 
schizophrenia. J Clin Psychiatry 1994;55 Suppl B:133-6.
25. Ghotbi R, Mannheimer B, Aklillu E, Suda A, Bertilsson L, Eliasson E, et al. 
Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced 
olanzapine exposure – an impact similar to male gender or smoking in 
schizophrenic patients. Eur J Clin Pharmacol 2010;66:465-74.
26. Skogh E, Bengtsson F, Nordin C. Could discontinuing smoking be hazardous 
for patients administered clozapine medication? A case report.  
Ther Drug Monit 1999;21:580-2.
27. Meyer JM. Individual changes in clozapine levels after smoking cessation: 
results and a predictive model. J Clin Psychopharmacol 2001;21:569-74.
28. Lawn S, Pols R. Smoking bans in psychiatric inpatient settings? A review of 
the research. Aust N Z J Psychiatry 2005;39:866-85.
29. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M,  
et al. Systematic overview of warfarin and its drug and food interactions.  
Arch Intern Med 2005;165:1095-106.
30. Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, Morarai T, Yodting T, 
Piriyachananusorn N. Assessing evidence of interaction between smoking and 
warfarin: a systematic review and meta-analysis. Chest 2011;139:1130-9.
31. Hochholzer W, Trenk D, Mega JL, Morath T, Stratz C, Valina CM, et al. Impact 
of smoking on antiplatelet effect of clopidogrel and prasugrel after loading 
dose and on maintenance therapy. Am Heart J 2011;162:518-26.
32. Park KW, Park JJ, Jeon KH, Kang SH, Oh IY, Yang HM, et al. Enhanced 
clopidogrel responsiveness in smokers: smokers’ paradox is dependent on 
cytochrome P450 CYP1A2 status. Arterioscler Thromb Vasc Biol 2011;31:665-71.
33. Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS. Interaction between 
cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 
2009;53:1273-8.
34. Berger JS, Bhatt DL, Steinhubl SR, Shao M, Steg PG, Montalescot G, et al.  
Smoking, clopidogrel, and mortality in patients with established 
cardiovascular disease. Circulation 2009;120:2337-44.
35. de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. 
Psychiatric Serv 2004;55:491-3.
36. Richter KP, Gibson CA, Ahluwalia JS, Schmelzle KH. Tobacco use and quit 
attempts among methadone maintenance clients. Am J Public Health 
2001;91:296-9.
37. Frosch DL, Stopshaw S, Nahom D, Jarvik ME. Associations between tobacco 
smoking and illicit drug use among methadone-maintained opiate-dependent 
individuals. Exp Clin Psychopharmacol 2000;8:97-103.
38. Chait LD, Griffiths RR. Effects of methadone on human cigarette smoking and 
subjective ratings. J Pharmacol Exp Ther 1984;229:636-40.
39. McCool RM, Paschall Richter K. Why do so many drug users smoke?  
J Subst Abuse Treat 2003;25:43-9.
40. Elkader AK, Brands B, Selby P, Sproule BA. Methadone-nicotine interactions 
in methadone maintenance treatment patients. J Clin Psychopharmacol 
2009;29:231-8.
41. Olivier D, Lubman DI, Fraser R. Tobacco smoking within psychiatric inpatient 
settings: biopsychosocial perspective. Aust N Z J Psychiatry 2007;41:572-80.
42. Schwingl PJ, Ory HW, Visness CM. Estimates of the risk of cardiovascular 
death attributable to low-dose oral contraceptives in the United States.  
Am J Obstet Gynecol 1999;180:241-9.
43. Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only 
contraceptives and cardiovascular risk: results from the Transnational Study 
on Oral Contraceptives and the Health of Young Women.  
Eur J Contracept Reprod Health Care 1999;4:67-73.
44. Lazarus S, Chinchilli V, Rollings N, Boushey H, Cherniack R, Craig T, et al. 
Smoking affects response to inhaled corticosteroids or leukotriene receptor 
antagonists in asthma. Am J Respir Crit Care Med 2007;175:783-90.
45. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking 
reduces histone deacetylase 2 expression, enhances cytokine expression, and 
inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001;15:1110-2.
46. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. 
Influence of cigarette smoking on inhaled corticosteroid treatment in mild 
asthma. Thorax 2002;57:226-30.
REFERENCES
